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Background: A link between uric acid (UA) levels and cardiovascular diseases has been previously reported. However,
its importance as a risk factor is still controversial. This study sought to determine whether elevated serum uric acid
levels are associated with cardiovascular disease (CVD) in middle-aged and elderly Chinese individuals.
Methods: We conducted a population-based cross-sectional study in Shanghai, with a total of 8510 participants aged
≥40 years. The CVD included diagnosed coronary heart disease (CHD) and stroke. MetS was defined according to the
updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian Americans.
Results: Uric acid levels were positively associated with BMI, waist circumference, triglycerides, systolic blood pressure,
diastolic blood pressure, glycohemoglobin, fasting plasma glucose, postprandial 2-hour plasma glucose (all P < 0.05),
and negatively associated with HDL-cholesterol (P < 0.001). The prevalence of CVD significantly increased with increasing
quartiles of UA in those without MetS group (p trend < 0.001), but not necessarily increased in those with MetS. After
adjustment for metabolic syndrome and other cardiovascular risk factors, multivariate logistic regression analysis showed
that odds ratios (OR) for CHD, stroke, and CVD in those in the fourth quartiles were 2.34 (95% confidence interval [CI]
1.73 to 3.45), 2.18 (95% CI 1.86 to 3.28), and 2.16 (95% CI 1.80 to 3.29), respectively, compared with those in the first
quartile of UA.
Conclusions: Elevated serum uric acid level was associated with CVD, independent of conventional cardiovascular
disease risk factors and metabolic syndrome.
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During the past two decades, China has experienced
rapid economic growth and the ageing of its population.
Resulting changes in lifestyle and longer life expectancy
have led to an increased burden of cardiovascular and
other chronic diseases [1-3]. The metabolic syndrome
(MetS) is characterized by a clustering of cardiovascular
risk factors. Previous studies have demonstrated an asso-
ciation of metabolic syndrome with the development of
cardiovascular disease (CVD) [3-5] and increased risk of
mortality from CVD [6,7].* Correspondence: suqingxinhua@163.com
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reproduction in any medium, provided the orUric acid is the metabolic end product of purine me-
tabolism in humans, excess accumulation can lead to
various diseases [8]. Recently, a series of controversial
and conflicting findings from epidemiological studies
were reported [9-21]. Previous studies have demon-
strated a strong relationship between serum uric acid
levels and coronary heart disease (CHD) and some stud-
ies suggested that uric acid may be an independent risk
factor for cardiovascular disease [9-17]. Moreover, re-
cently a meta-analysis showed that hyperuricemia may
increase the risk of CHD events, independently of trad-
itional CHD risk factors [18]. However, the nature of the
relationship between uric acid and cardiovascular disease
remains a subject of debate [19-21].
Furthermore, although previous studies have analyzed
the relationship between uric acid and CVD, thus far,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Flow chart of the recruitment and selection procedure
of the study population.
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tionship between uric acid and CVD in Chinese people
is scarce. In the present study, we undertook in large-
scale Chinese populations. We first investigated the as-
sociation between uric acid levels and confounding
factors including metabolic syndrome. In addition, we
also assessed whether there is an independent associ-
ation of uric acid with cardiovascular disease in individ-
uals subdivided according to metabolic syndrome status.
Methods
Study population and design
From May 2011 and November 2011, a population-
based cross-sectional survey (Chongming Health Investi-
gation) was conducted in Chongming District, Shanghai,
China. A two-stage stratified sampling method was used.
First, 12 residential communities or streets were ran-
domly selected from the Chongming District. Of these, 8
urban communities and 4 rural communities were
chosen to represent people with high to low socioeco-
nomic status. Secondly, Within each community/street,
all eligible individuals were sampled, with the exception
that in households with more than one eligible individ-
ual, one individual was randomly selected. During the
recruiting phase, inhabitants aged ≥40 years in these 12
communities were invited by telephone or door-to-door
visit to participate in this study. A total of 9,930 subjects
completed the survey, yielding a response rate of 92.4%.
Each participant signed an informed consent form be-
fore completing the questionnaire. The protocol was ap-
proved by the Institutional Review Board of Xinhua
Hospital affiliated with Shanghai Jiao-Tong University
School of Medicine.
After excluding subjects with missing data regarding
serum uric acid (n = 1194) or coronary heart disease (n =
129) or stroke (n = 97), 8510 participants were included in
the final analysis (Figure 1).
Data collection
A standardized questionnaire was used by trained physi-
cians to collect information such as age, sex, medica-
tions, education level (6, 7–9, or ≥10 years in school).
The history of chronic diseases and current use of medi-
cations were recorded. The smoking or alcohol con-
sumption habit was defined as never, current (smoking
or consuming alcohol regularly in the past 6 months), or
ever (cessation of smoking or alcohol consumption for
more than 6 months). The type, amount, and frequency
of alcohol consumption were collected. Based on the al-
cohol content of the beverages reported, mean daily al-
cohol consumption was calculated and expressed in
grams per day. Physical activity at leisure time was esti-
mated using the short form of the International Physical
Activity Questionnaire by adding questions on frequencyand duration of moderate and vigorous activities and
walking [22].
Anthropometric measurements were performed by the
trained personnel using a standardized protocol. Height
was measured to the nearest 0.1 cm, and weight was re-
corded to the nearest 0.1 kg while participants were
wearing lightweight clothing and no shoes. Body mass
index (BMI) was defined as body weight in kilograms di-
vided by height squared in meters. Waist circumference
(WC) was measured to the nearest 0.1 cm at the umbil-
ical level with the participant in a standing position. Hip
circumference was measured over the widest part of the
gluteal region, and the waist-to-hip ratio was calculated
as a measure of central obesity. Three blood pressure re-
cordings were obtained from the right arm of patients in
a sitting position after 30 min of rest; measurements
were taken in 5-min intervals, and mean values were
calculated.
Biochemical measurements
Peripheral venous blood samples were collected after an
overnight fast. The fasting glucose, glucose 2 h after oral
glucose tolerance test were measured with the use of the
glucose oxidase method on an autoanalyzer (Modular
P800; Roche, Basel, Switzerland). Triglycerides (TG), total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-c), low-density lipoprotein cholesterol (LDL-c), and
serum uric acid were measured using chemiluminescence
methods on the autoanalyzer (Modular E170; Roche). Gly-
cated hemoglobin(HbA1c) was measured with the use of
the Chromatography method on an autoanalyzer (D10;
Bio-Rad, USA).
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Hypertension was defined as diastolic blood pressure ≥90
mm Hg, systolic blood pressure of ≥140 mm Hg, or
current medication for hypertension (as defined by WHO
1999) [16]. Coronary heart disease (CHD) and stroke were
defined using the WHO MONICA criteria [23]. Myocar-
dial infarction was diagnosed by a representative set of
electrocardiogram, cardiac enzyme values, and typical
symptoms. Angina was defined as use of nitroglycerine,
experience of typical chest pain, and electrocardiogram
changes compatible with ischemic heart disease. Strokes
were defined as events requiring hospitalization; this infor-
mation was verified from local hospital records, and 82%
of the cases were confirmed using computed tomography
and magnetic resonance imaging. Cardiovascular disease
in the present study was defined by the presence of one or
more of these two outcomes: CHD and stroke. Subjects
with a fasting plasma glucose level of 7.0 mmol/l and/or a
2-h plasma glucose level of 11.1 mmol/l during an oral
glucose tolerance test and/or who were receiving antidia-
betic medications were diagnosed with diabetes mellitus.
The diagnosis of cardiovascular events was based on self-
reports, confirmed by hospital medical records and further
clinical examinations carried out at the time of the survey
(including electrocardiogram and ankle-arm systolic blood
pressure index).
Definition of MetS
The MetS was defined based upon the updated NCEP-
ATPIII for Asian Americans [24] as presenting 3 or
more of the following components: 1) waist cirumfer-
ence ≥90 cm for men or ≥80 cm for women; 2) triglycer-
ides ≥1.7 mmol/l; 3) HDL cholesterol <1.03 mmol/l for
men or <1.30 mmol/l for women; 4) blood pressure
≥130/85 mm Hg or current use of anti-hypertensive
medications; and 5) fasting glucose ≥5.6 mmol/l or pre-
viously diagnosed type 2 diabetes or on oral antidiabetic
agents or insulin.
Statistical analysis
Normally distributed data were expressed as means ±
SD, whereas variables with a skewed distribution were
reported as median (interquartile range) and log trans-
formed to approximate normality before analysis. Cat-
egorical variables were represented by frequency and
percentage. The association of demographic, medical,
metabolic and clinical characteristics with serum uric
acid quartiles was assessed using multivariate linear or
logistic regression analyses, adjusting for age and gender,
for continuous and dichotomous variables, respectively.
The correlations among serum uric acid, anthropometric
indices and metabolic features adjusting for age and gen-
der were obtained using Spearman partial correlation
analysis. Sampling weights was used when estimatingprevalence of CVD. The trend for age- and sex-adjusted
prevalence of CVD according to quartile of uric acid and
the presence of metabolic syndrome were analysed using
linear regression model. Multivariate logistic regression
models were used to estimate the odds ratios (ORs) for
CHD, stroke and CVD. Potential confounding variables
including age, gender, smoking, alcohol drinking, phys-
ical activity, educational level, education, BMI, and
metabolic syndrome were controlled in the regression
models. All statistical analysis were performed with the
SPSS Statistical Package (version 15.0; SPSS Inc., Chicago,
IL). P < 0.05 was considered statistically significant.
Results
Characteristics of participants according to serum uric
acid quartiles
Included were 8510 individuals who had both uric acid
and CVD assessments (Figure 1). The mean age of this
cohort was 55.90 ± 7.89 years, and approximately 32%
were men. Baseline demographic and medical character-
istics for both genders combined and divided by uric
acid quartiles are presented in Table 1. Higher uric acid
levels were associated with higher proportion of meta-
bolic syndrome, proportion of men, age, smoking, alco-
hol consumption, systolic blood pressure, diastolic blood
pressure, BMI, waist circumference, hip circumference,
waist to hip ratio, fasting plasma glucose, postprandial
2-hour plasma glucose, glycohemoglobin, triglycerides,
total cholesterol, LDL-cholesterol, presence of stroke,
presence of CHD, hypertension, diabetes (all P < 0.05).
In contrast, the patients with higher uric acid levels
displayed lower levels of HDL cholesterol (P < 0.001)
(Table 1).
Association between serum uric acid and CHD, stroke
and CVD
Partial Spearman correlation analysis demonstrated the
strongest correlation between uric acid and triglycerides
among various metabolic features (Table 2). Moreover
there was strong partial correlation between uric acid
and BMI, TC, Waist circumference (WC), systolic blood
pressure (SBP) and diastolic blood pressure (DBP),
adjusting for age and gender, (all P < 0.001) (Table 2). As
presented in Table 3, the ORs for CHD, stroke and CVD
were higher with increasing uric acid quartiles (all p <
0.001 for linear trend). In the highest uric acid quartile,
the adjusted ORs of CHD, stroke and CVD were 2.34
(95% confidence interval [CI] 1.73 to 3.45), 2.18 (95% CI
1.86 to 3.27), and 2.16 (95% CI 1.80 to 3.29), respect-
ively, compared with those in the first quartile of UA
(Table 3).
We further analyzed the prevalence of CVD according
to quartile of uric acid and the presence of metabolic
syndrome. After adjustments for age, gender, alcohol
Table 1 Characteristics of study participants according to uric acid quartiles
Characteristics Q1 Q2 Q3 Q4 P value
(n = 2428) (n = 2114) (n = 1986) (n = 1982)
≤0.2 0.21-0.24 0.25-0.29 ≥0.30
MetS (%) 927 (38.2) 1112 (52.6) 1210 (60.9) 1410 (71.1) <0.001
Uric acid (mmol/L) 0.18 (0.16-0.19) 0.22 (0.22-0.24) 0.27 (0.26-0.28) 0.34 (0.31-0.37) <0.001
Male n (%) 316 (13.02) 500 (23.65) 705 (35.52) 1205 (60.80) <0.001
Age (yrs)b 53.29 ± 7.97 55.72 ± 7.75 57.25 ± 7.45 57.93 ± 7.46 <0.001
Smoking (yes) 413 (17.02) 411 (19.44) 501 (25.23) 680 (34.31) <0.001
Alcohol (yes) 524 (21.59) 514 (24.31) 579 (29.15) 852 (42.99) <0.001
SBP (mmHg) 125 ± 20 129 ± 21 132 ± 20 135 ± 19 <0.001
DBP (mmHg) 78 ± 10 80 ± 10 81 ± 11 83 ± 10 <0.001
BMI (kg/m2) 23.41 ± 3.19 24.76 ± 8.45 25.53 ± 11.29 25.79 ± 4.49 <0.001
Waist circumference (cm) 80 ± 10 84 ± 12 86 ± 10 89 ± 9 <0.001
Hip circumference (cm) 94.07 ± 7.40 95.85 ± 7.00 96.85 ± 6.78 98.09 ± 6.89 <0.001
Fasting plasma glucose (mmol/L) 6.05 ± 1.50 6.39 ± 1.89 6.50 ± 1.80 6.53 ± 1.61 <0.001
P2hPG (mmol/L) 7.95 ± 3.49 8.88 ± 4.16 9.26 ± 4.04 9.36 ± 3.91 <0.001
HbA1C 5.84 ± 0.97 6.01 ± 1.10 6.05 ± 1.07 6.02 ± 0.94 0.021
Triglycerides (mmol/L)c 1.09 (0.82-1.52) 1.36 (0.98-1.93) 1.49 (1.06-2.24) 1.86 (1.29-2.67) <0.001
Total cholesterol (mmol/L) 4.59 ± 0.99 4.79 ± 0.99 4.81 ± 1.01 4.88 ± 1.05 <0.001
LDL cholesterol (mmol/L) 2.56 ± 0.75 2.66 ± 0.76 2.72 ± 0.79 2.72 ± 0.78 <0.001
HDL cholesterol (mmol/L) 1.33 ± 0.33 1.27 ± 0.31 1.22 ± 0.31 1.17 ± 0.30 <0.001
Physical activity 0.191
Low 1795 (73.96) 1538 (72.75) 1453 (73.16) 1395 (70.38)
Moderate 487 (20.07) 435 (20.58) 397 (19.99) 438 (22.10)
High 145 (5.97) 141 (6.67) 136 (6.85) 149 (7.52)
Education 0.061
0-6 520 (21.43) 516 (24.41) 497 (25.03) 464 (23.41)
7-9 1217 (50.14) 1048 (49.57) 989 (47.80) 988 (49.85)
≥10 690 (28.43) 550 (26.02) 500 (27.17) 530 (26.74)
Stroke 69 (2.84) 84 (3.97) 99 (4.98) 168 (8.48) <0.001
Coronary heart disease 149 (6.14) 171 (8.09) 233 (11.73) 379 (19.12) <0.001
Hypertension 1029 (42.40) 1109 (52.46) 1213 (61.08) 1386 (69.93) <0.001
Diabetes mellitus 319 (13.14) 453 (21.43) 574 (28.90) 622 (31.38) <0.001
Anti-hypertension medications 342 (14.09) 351 (16.60) 394 (19.84) 448 (22.60) <0.001
Anti-diabetic medications 110 (4.53) 111 (5.25) 140 (7.05) 119 (6.00) 0.003
Lipid-lowering medications 65 (2.68) 71 (3.36) 62 (3.12) 57 (2.88) 0.571
SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; P2hPG, postprandial 2-hour plasma glucose; HbA1C, Glycated hemoglobin;
LDL, Low-density lipoprotein; HDL, high–density lipoprotein.
aData are presented as mean ± SD, median (interquartile range), or number (percent); P value was calculated after adjustment for age, gender.
bNot adjusted for itself.
cThis variables was log transformed before analysis.
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the prevalence of CVD in subjects with metabolic syn-
drome increased with uric acid quartile (p < 0.001 for
linear trend) (Figure 2). No trend was observed in sub-
ject without metabolic syndrome (p = 0.217 for linear
trend).Discussion
In the present study, we found that serum uric acid levels
showed association with the risk of CVD from the cross-
sectional data in middle-aged and elderly Chinese individ-
uals, independent of conventional cardiovascular risk
factors including components of metabolic syndrome.
Table 2 Partial Spearman correlation coefficients among uric acid, anthropometric indicators, and metabolic features
Uric acid BMI WC HC WHR SBP DBP FPG P2hPG HbA1c TC TG HDL-c
BMI 0.11b
WC 0.21b 0.33b
HC 0.11b 0.34b 0.67b
WHR 0.08b 0.11b 0.47b −0.11b
SBP 0.10b 0.11b 0.23b 0.17b 0.12b
DBP 0.14b 0.11b 0.23b 0.19b 0.09b 0.62b
FPG 0.04b 0.02c 0.09b 0.03c 0.07b 0.14b 0.10b
P2hPG 0.09b 0.05b 0.12b 0.07b 0.08b 0.15b 0.11b 0.76b
HbA1c 0.02c 0.02c 0.07b 0.03c 0.05b 0.05b 0.03c 0.82b 0.71b
TC 0.12b 0.02 0.08b 0.05b 0.04b 0.12b 0.13b 0.12b 0.10b 0.08b
TG 0.27b 0.09b 0.21b 0.13b 0.11b 0.11b 0.15b 0.18b 0.21b 0.14b 0.23b
HDL-c −0.18b −0.09b −0.17b −0.12b −0.07b 0.02c 0.00 −0.04b −0.09b −0.10b 0.49b −0.29b
LDL-c 0.08b 0.02 0.06b 0.07b 0.02c 0.07b 0.08b 0.08b 0.05b 0.08b 0.86b −0.04c 0.33b
BMI, body mass index; WC, Waist circumference, HC, Hip circumference; WHR, Waist-hip-ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; FPG, fasting
plasma glucose; P2hPG, postprandial 2-hour plasma glucose; HbA1C, Glycated hemoglobin; TC, Triglycerides; Total cholesterol; TG, LDL, Low-density lipoprotein; HDL,
high–density lipoprotein.
aAll correlation coefficients were calculated after adjustment for age, gender.
bP < 0.001.
cP < 0.05.
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the relationship between serum uric acid levels and car-
diovascular diseases [9-17,25]. Increased serum uric acid
was found to be associated with important risk factors for
atherosclerosis like hypertension [26-29], abdominal obes-
ity [28], diabetes mellitus [29,30], the metabolic syndrome
[17], hypertriglyceridemia [31], endothelial dysfunctionTable 3 Odds ratios and 95% confidence interval for cardiova
Q1 Q2
OR (95% CI) OR (95% CI)
CHD
Model 1* 1 1.73 (1.36-2.19)
Model 2† 1 1.71 (1.35-2.17)
Model 3‡ 1 1.65 (1.28-2.14)
Stroke
Model 1* 1 1.40 (1.02-1.96)
Model 2† 1 1.36 (1.03-1.93)
Model 3‡ 1 1.30 (1.02-1.81)
CVD
Model 1* 1 1.39 (1.14-1.68)
Model 2† 1 1.31 (1.11-1.62)
Model 3‡ 1 1.28 (1.09-1.56)
*Model 1 adjusted for age and gender.
†Model 2 further adjusted for alcohol drinking, smoking, education, physical activity
antihyperlipidemic therapy and antihyperglycemic therapy).
‡Model 3 further adjusted for metabolic syndrome and BMI.[32] and renal failure [33]. However, whether uric acid is
an independent risk factor for cardiovascular mortality is
still a controversy. Difficulties in determining whether uric
acid should be considered a cardiovascular risk factor may
be explained by its frequent association with other cardio-
vascular risk factors [34] for which uric acid is considered
as a risk marker or epiphenomenon or even an adaptivescular disease according to quartile of serum uric acid
Q3 Q4 P value
for trendOR (95% CI) OR (95% CI)
1.95 (1.70-2.45) 2.56 (1.95-3.89) <0.001
1.90 (1.63-2.42) 2.45 (1.82-3.56) <0.001
1.82 (1.63-2.35) 2.34 (1.73-3.45) <0.001
1.74 (1.29-2.43) 2.41 (2.02-3.65) <0.001
1.67 (1.27-2.41) 2.27 (1.92-3.39) <0.001
1.60 (1.23-2.29) 2.18 (1.86-3.28) <0.001
1.87 (1.54-2.44) 2.50 (2.09-3.47) <0.001
1.77 (1.49-2.48) 2.40 (2.06-3.40) <0.001
1.64 (1.35-2.38) 2.16 (1.80-3.29) <0.001
, TC, LDL and treatments (including antihypertensive therapy,
Figure 2 Prevalence of CVD according to quartiles of uric acid and the presence of metabolic syndrome (adjusted for age, gender,
alcohol drinking, smoking, education, physical activity, TC, LDL). Data are expressed as percentages ± SE. P < 0.001 for trend in MS(−) group,
and p = 0.217 for trend in MS(+) group.
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dant properties [35] and the controversial and conflicting
findings from epidemiological studies [36].
The metabolic syndrome is characterized by a clustering
of cardiovascular risk factors, including abdominal obesity,
high blood pressure, increased glucose concentration, and
dyslipidemia, is a common basis for the development of
atherosclerosis, especially CVD [37-39]. Moreover, previ-
ous studies claimed that hyperuricemia was a new compo-
nent of metabolic syndrome. Furthermore, in our study,
the proportion of metabolic syndrome is in parallel with
increasing serum uric acid quartiles. Thus, in order to ex-
plore whether elevated serum uric acid levels are associ-
ated with CVD independent of metabolic syndrome, we
further analyzed the prevalence of CVD according to
quartile of uric acid and the presence of metabolic syn-
drome. We found that prevalence of CVD is significantly
increased with increasing quartiles of uric acid in without
MetS group (p trend < 0.001), but not necessarily in-
creased in those with metabolic syndrome. Additional fac-
tors besides metabolic syndrome may also play a key role
in the development of CVD in hyperuricemia subjects,
which requires further research.
The present study may have some implications. In par-
ticular, this study may strengthen the need for interven-
tional studies with uric acid-lowering therapies to
maintain UA levels in the lower safe range. Moreover,
allopurinol – a xanthine oxidase inhibitor – has been
shown recently to significantly improve endothelialfunction and abolish vascular oxidative stress [40], has a
clinically relevant antiischaemic effect and has been well
tolerated in patients with angina [41]. In analogy with
homocysteine-lowering therapy interventional studies
with UA-lowering agents, apart from exploring clinical
benefits of these agents, may provide valuable additional
information regarding causality in the uric acid–cardio-
vascular disease relationship.
The major strength of our present study was that the
large sample size and representative sample with a rela-
tively high response rate. Several limitations of our study
have also to be addressed. First, due to the cross-
sectional nature of the present study, no causal relation-
ships can be established. Large prospective studies are in
urgent need to confirm the relationship between serum
uric acid levels and CVD. Second, although most poten-
tial confounders were carefully controlled, since some of
the study subjects may had several chronic disease, we
could not eliminate the possible effect of underlying dis-
eases and medications used for these diseases on the
present findings.
Conclusion
In conclusion, the present study showed that elevated
serum uric acid level was associated with CVD, inde-
pendent of conventional CVD risk factors and the pres-
ence of metabolic syndrome. The study added more
evidence to the notion that the risk of CVD increased in
subjects with hyperuricemia.
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